CAJ | 학술논문

目的分析晚期非小细胞肺癌(NSCLC)患者抗血管生成治疗前后外周血中循环内皮祖细胞(cEPCs)的变化,探讨cEPCs在NSCLC中的应用价值.方法采用吉西他滨+顺铂化疗(GP)方案联合重组人血管内皮抑素(实验组)及单用GP方案(对照组)治疗晚期NSCLC患者52例,流式细胞法检测治疗前后cEPCs水平.结果实验组组临床有效率为44.0％,对照组为25.9％(P=0.245);实验组临床受益率为80.0％,对照组为51.8％ (P =0.044);实验组cEPCs平均下降(0.041±0.044)％,对照组平均下降(0.011 ±0.047)％ (P＜ 0.05).结论化疗联合抗血管生成治疗治疗晚期NSCLC优于单用化疗,cEPCs可以作为有效的疗效预测指标.
목적 분석만기비소세포폐암(NSCLC)환자항혈관생성치료전후외주혈중순배내피조세포(cEPCs)적변화,탐토cEPCs재NSCLC중적응용개치.방법 채용길서타빈+순박화료(GP)방안연합중조인혈관내피억소(실험조)급단용GP방안(대조조)치료만기NSCLC환자52례,류식세포법검측치료전후cEPCs수평.결과 실험조조림상유효솔위44.0％,대조조위25.9％(P=0.245);실험조림상수익솔위80.0％,대조조위51.8％ (P =0.044);실험조cEPCs평균하강(0.041±0.044)％,대조조평균하강(0.011 ±0.047)％ (P＜ 0.05).결론 화료연합항혈관생성치료치료만기NSCLC우우단용화료,cEPCs가이작위유효적료효예측지표.
Objective To investigate the changes and clinical value of circulating endothelial progenitor cells (cEPCs) in the peripheral blood of advanced non-small cell lung cancer(NSCLC) patients.Methods Fifty-two advanced NSCLC patients were randomly divided into the experimental group (treated with GP plus recombinant human endostatin)and control group (treated with GP alone).The levels of cEPCs pre-treatment and posttreatment were measured by flow cytometry.Results The response rate and benefit rate was 44.0％,80.0％ in the experimental group,and 25.9％,51.8％ in the control group,(P =0.245 and P =0.044,respectively).The number of cEPCs decreased by (0.041 ±0.044)％ in the experimental group,(0.011 ±0.047)％ in the control group (P ＜ 0.05 ).Conclusions Chemotherapy combined with antiangiogenic therapy is superior to chemotherapy alone in treatment of NSCLC.CEPCs may act as an effective biomarker in predicting the efficacy of antiangiogenic therapy.